1. Scrip
  2. >>Therapy Areas

Tiny Mabion Races Big Pharma To EU Rituximab Market

 
• By John Davis

Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.

Maciej Wieczorek
Mabion's President Maciej Wieczorek • Source: Mabion SA

Poland’s fledgling biotech company, Mabion SA, believes it is among the leaders in the race to develop a biosimilar version of Roche's monoclonal antibody, MabThera/Rituxan (rituximab), for Europe, but it needs to finalize a tie-up with a marketing partner or partners fast, as they will need time to prepare to compete against biosimilar heavyweights that are also developing versions of the blockbuster TNF-inhibitor.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.